Due to the complexity and diversity of sialic acids, it is possible that other ligands of Siglec‐G, such as CD52, may also interact with Siglec‐G on T cells.[52] Furthermore, treatment of tumor cells with sialidase resulted in a slightly enhanced killing ability of Siglecg−/− T cells, Therefore, Siglec‐9 or Siglec‐15 may have redundant roles with Siglec‐G, warranting further investigation. The gene discussed is SIGLEC9; the disease is neoplasm.